ResMed Chairman & CEO Michael Farrell files Form 4 for RSUs

Rhea-AI Filing Summary

ResMed Inc. (RMD) Chairman and CEO Michael J. Farrell reported routine equity compensation activity. On 11/20/2025, he acquired 13,551 shares of ResMed common stock at $0, following the earning of performance-based restricted stock units that were granted on November 16, 2022 and certified as earned by the compensation and leadership development committee.

On the same date, 7,297 shares were disposed of at $0 to ResMed to cover tax withholding on the vesting. After these transactions, Farrell beneficially owned 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	11/20/2025		A(1)		13,551	A	$0	473,520	D
ResMed Common Stock	11/20/2025		F(2)		7,297	D	$0	466,223	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met.

2. Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on November 16, 2022.

	Michael J. Farrell, Chairman and CEO	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) report for Michael J. Farrell?

ResMed reported that Michael J. Farrell, its Chairman and CEO, acquired 13,551 shares of ResMed common stock on 11/20/2025 upon vesting of performance-based restricted stock units.

Why did Michael J. Farrell dispose of ResMed (RMD) shares in this Form 4?

The Form 4 states that 7,297 shares of ResMed common stock were disposed of to the issuer for tax withholding related to the vesting of performance-based restricted stock units granted on November 16, 2022.

How many ResMed (RMD) shares does Michael J. Farrell own after this transaction?

Following the reported transactions, Michael J. Farrell beneficially owned 466,223 shares of ResMed common stock directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

What type of equity award vested for ResMed (RMD) CEO Michael J. Farrell?

The filing explains that the transaction involved performance-based restricted stock units granted on November 16, 2022, which were earned on November 20, 2025 when performance metrics were certified as met.

What is Michael J. Farrell’s role and relationship to ResMed (RMD)?

Michael J. Farrell is reported as both a Director and an Officer of ResMed Inc., serving as its Chairman and CEO.

Is this ResMed (RMD) Form 4 filed by more than one reporting person?

No. The Form 4 indicates it is filed by one reporting person, Michael J. Farrell.